Ischemix, Inc. is focused on developing innovative cytoprotective therapies aimed at treating serious diseases, with its lead compound, CMX-2043, currently in preclinical development for traumatic brain injury (TBI). CMX-2043 is a novel chemical entity that has shown promising preclinical results, demonstrating significant improvements in sensorimotor activity, cognition, and memory in various controlled studies. The compound's efficacy is supported by its ability to enhance microstructural integrity of brain tissue, improve brain metabolite levels, and reduce oxidative stress, making it a strong candidate for addressing the complex challenges associated with TBI. Additionally, CMX-2043 is protected by multiple patents covering its composition and methods of use.

The technology behind Ischemix's compounds is rooted in the use of alpha lipoic acid, a natural co-factor known for its antioxidant and anti-inflammatory properties. This compound is linked to sequences of natural amino acids, enhancing its potency compared to alpha lipoic acid alone. CMX-2043 activates the cytoprotective kinase protein kinase B (Akt) through the phosphatidylinositide 3-kinase (PI3K) pathway, which is crucial for its protective effects in cellular and tissue models. The ongoing research and clinical trials for CMX-2043 highlight its potential not only for TBI but also for other therapeutic indications, showcasing Ischemix's commitment to advancing cytoprotective therapies.

United States

Ischemix is a privately-held pharmaceutical company that has developed novel cytoprotective compounds for the prevention and treatment of serious conditions of the kidney, heart and other organ systems.

Ischemix

Company Details